At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Regular Novolin R +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Center Safety and Tolerability Trial of Intranasal Insulin in Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Regular Novolin R and Placebo for Parkinson Disease. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartFeb 2020
First PostedFeb 2020
Primary CompletionAug 2024
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartFeb 4, 2020
Primary CompletionAug 27, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 6.4 years ago
Interventions
Regular Novolin Rdrug
Intranasal insulin
Placebodrug
Intranasal placebo (0.9% saline)